Second-look laparoscopy prior to proposed second-look laparotomy.

A prospective study was carried out to evaluate the use of second-look laparoscopy in patients in complete clinical remission after prolonged chemotherapy for advanced ovarian adenocarcinoma. Twenty-two patients with FIGO stages IIB, III, and IV ovarian adenocarcinoma underwent second-look laparoscopy after a median of 23 months of therapy. Eight (36.

Cystadenocarcinoma of the ovary in a 4-year-old: benign transformation during therapy.

Ovarian tumors comprise only 1% of all tumors in females below the age of 17 years. Of these, the epithelial tumors are the least common, being particularly rare before puberty and then increasing in frequency with advancing age after puberty. The youngest girl previously reported in the literature with an epithelial ovarian tumor was a 9-year-old child with an ovarian papillary cystadenocarcinoma.

Doxorubicin, cyclophosphamide, and 5-fluorouracil in patients with carcinoma of the cervix or vagina.

Thirty-six evaluable patients with carcinoma of the uterine cervix or vagina not amenable to surgery or radiation therapy were treated with doxorubicin, cyclophosphamide, and 5-fluorouracil; 16.5% of the patients responded, with 2.7% having a complete response.

Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.

A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. One hundred fourteen patients were included in the study: 70 received Delalutin and 44 Depo-Provera. There was no significant increase in the objective response or survival between the Delalutin or Depo-Provera patients.

Weekly cis-diamminedichloroplatinum(II): active third-line chemotherapy in ovarian carcinoma--a preliminary report.

Ten evaluable patients with progressive ovarian adenocarcinoma received third-line chemotherapy consisting of weekly cisplatin (cis-diamminedichloroplatinum[II]) at a dose of 1 mg/kg weekly for a maximum of 6 weeks followed by 60 mg/m2 every 3 weeks. There was no life-threatening toxicity. Seven patients (70%) achieved an objective partial response.

Para-aortic node biopsy in staging women with cervical, ovarian and endometrial carcinoma: a review.

In women with gynecologic malignancies the para-aortic lymph nodes are not routinely treated. However, pretherapy surgical staging has now disclosed an incidence of para-aortic node metastasis of 10.3% for presumed stage I and II ovarian cancer, 8.

Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream.

Eight patients with squamous cell carcinoma in situ of the vagina were treated with monthly 5 day courses of 20% 5-fluorouracil cream applied to the vagina. Seven (87.5%) of the women had an initial complete response; however, three subsequently developed recurrence after the treatment was stopped.

A prospective trail comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma.

From 1958 to 1967, a prospective randomized trial was conducted in 189 women with stage I, group I endometrial adenocarcinoma, comparing treatment by hysterectomy alone, preoperative uterine radium followed by hysterectomy, and hysterectomy and postoperative vaginal radium. All women have been followed for a minimum of 10 years. The actual survival rate at 5 years for all patients was 94.

Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.

High-dose methotrexate with leucovorin rescue plus cyclophosphamide resulted in a 66.6% objective response rate with a 50% complete response rate. These preliminary results are higher than our previous results with melphalan alone or actinomycin D, 5-fluorouracil, and cyclophosphamide in women with advanced ovarian adenocarcinoma.

Adriamycin in localized and metastatic uterine sarcomas.

Seventeen women with metastatic uterine sarcomas were treated with Adriamycin chemotherapy. Only one (6%) had an objective response. In addition, 12 patients with early uterine sarcomas were randomized to Adriamycin versus no adjuvant chemotherapy in order to evaluate the effect of Adriamycin in reducing the incidence of subsequent distant recurrences.

Incidence of subclinical metastasis in stage I and II ovarian carcinoma.

The incidence of unsuspected metastasis to the diaphgram, retroperitoneal lymph nodes, and omentum as well as malignant cytologic peritoneal washings in women with presumed localized ovarian cancer is presented. Of the women with presumed Stage I ovarian cancer, from our clinical experience and those reported in the literature, 11.3% were found to have diaphragmatic metastases, 13.

Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina.

One hundred consecutive evaluable patients with advanced carcinoma of the cervix or vagina were treated with doxorubicin (Adriamycin) alone or in combination. The use of Adriamycin in conjunction with cyclophosphamide and 5-fluorouracil resulted in the highest response rate with all responders continuing to respond.

Microinvasive carcinoma of the vulva.

A case is presented of a patient with microinvasive carcinoma of the vulva which was treated by conservative surgery. Six years later, the patient developed inguinal and pelvic lymph node recurrence of carcinoma. A review of the literature on similar cases is also presented.

Melphalan chemotherapy in advanced ovarian carcinoma.

One hundred and eleven consecutive women with FIGO Stages III and IV ovarian adenocarcinoma were treated with melphalan as their initial chemotherapy. The response rate was 19.8% with 10.